In conclusion, our results indicate that disrupting LIF signaling, which directly fuels oncogenic KRAS-driven pancreatic adenocarcinoma, has an impact on tumorigenicity of KRAS and overcomes the characteristic resistance to chemotherapy. The gene discussed is LIF; the disease is pancreatic adenocarcinoma.